![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 01, 2021 4:42:31 PM
MyMD PHARMA'S PATHS TO SUCCESS
1. MyMD DEVELOPES WORLD'S 1ST 2nd GENERATION TNF-alpha MODULATOR.
2. LAB COMPARISONS OF MYMD-1 WITH 3 POPULAR JAK STAT BLOCKERS FINDS
IT TO BE EQUALLY EFFECTIVE, GIVING IT THE OPPORTUNITY TO GARNER
A PORTION OF THIS MARKET.
3. MyMD EXPECTS TO OFFER ALL HUMANS OVER THE AGE OF 64 THE OPPORTUNITY
TO LIVE LONGER, AND HEALTHIER WHILE DOING SO. IT ALSO SEES THE SAME
BENEFIT TO ALL OTHER MAMMALS WHO REACH COMPARABLE AGES.
Recent MYMD News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 01:04:23 PM
- MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer • Business Wire • 06/17/2024 01:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 01:10:03 PM
- MyMD Pharmaceuticals Secures Strategic Investments • Business Wire • 05/21/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 04:00:19 PM
- MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • Business Wire • 03/05/2024 02:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:13:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:27:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:57:03 PM
- MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • Business Wire • 02/13/2024 04:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:15:12 PM
- MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis • Business Wire • 12/06/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 01:00:10 PM
- MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain • Business Wire • 10/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:30:23 PM
- MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 • Business Wire • 10/04/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:24:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/24/2023 09:58:33 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM